Inicio
Fármacos Antitumorales
Proteinas quinasas, cáncer y metástasis.

6. Bibliografía


6.    Bibliografía

1.
G. Manning, D. B. Whyte, R. Martinez, T. Hunter, and S. Sudarsanam (2002) "The Protein Kinase Complement of the Human Genome" Science 6 December 2002: Vol. 298. no. 5600, pp. 1912 - 1934
2.
Roux PP, Blenis J. "ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions." Microbiol Mol Biol Rev. 2004 Jun;68(2):320-44. Review.
3.
Cobb, M.H. (1999) "MAP kinase pathways." Prog. Biophys. Mol. Biol. 71, 479-500.
4.
Weston, C.R. and Davis, R.J. (2002) "The JNK signal transduction pathway." Curr. Opin. Genet. Dev. 12, 14-21.
5.
Whitmarsh, A.J. and Davis, R.J. (1998) "Structural organization of MAP-kinase signaling modules by scaffold proteins in yeast and mammals." Trends Biochem. Sci. 23, 481-485.
6.
Carpenter, G. (2003) "Nuclear localization and possible functions of receptor tyrosine kinases." Curr. Opin. Cell Biol. 15, 143-148.
7.
Mendelsohn, J. and Baselga, J. (2003) "Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer."J Clin. Oncol. 21, 2787-2799.
8.
Yarden, Y. and Sliwkowski, M.X. (2002)" Untangling the ErbB signalling network."Nat. Rev. Mol. Cell Biol. 2, 127-137.
9.
Dikic, I. and Blaukat, A. (1999) "Protein tyrosine kinasemediated pathways in G protein-coupled receptor signaling." Cell Biochem. Biophys. 30, 369-387.
10.
Gutkind, J.S. (2000) "Regulation of mitogen-activated protein kinase signaling networks by G protein-coupled receptors." Sci STKE. July 11; 2000 (40):RE1.
11.
Marinissen, M.J. and Gutkind, J.S. (2001) "G-protein-coupled receptors and signaling networks: emerging paradigms." Trends Pharmacol Sci. 22, 368-376.
12.
Van Haastert, P.J.M. and Devreotes, P.N. (2004) "Chemotaxis: signalling the way forward. "Nat. Rev. Mol. Cell Biol. 5, 626-634.
13.
Brakebusch, C. and Fassler, R. (2003) "The integrin-actin connection, an eternal love affair. "EMBO J. 22, 2324-2333.
14.
Kumar, R. and Vadlamudi, R.K. (2002) "Emerging functions of p21-activated kinases in human cancer cells." J. Cell. Physiol. 193, 133-144.
15.
Pollard, T.D. and Borisy, G.G. (2003)" Cellular motility driven by assembly and disassembly of actin filaments. "Cell 112, 453-465.
16.
Lee, J. T., Jr. and J. A. McCubrey (2002). "The Raf/MEK/ERK signal transduction cascade as a target for chemotherapeutic intervention in leukemia." Leukemia 16(4): 486-507.
17.
Dhillon, A. S. and W. Kolch (2002). "Untying the regulation of the Raf-1 kinase."Arch Biochem Biophys 404(1): 3-9.
18.
Dong, C., R. J. Davis, Flavell RA. (2002). "MAP kinases in the immune response."Annu Rev Immunol 20: 55-72.
19.
English, J. M. and M. H. Cobb (2002). "Pharmacological inhibitors of MAPK pathways." Trends Pharmacol Sci 23(1): 40-5.
20.
Schaeffer, H. J. and M. J. Weber (1999). "Mitogen-activated protein kinases: specific messages from ubiquitous messengers." Mol Cell Biol 19(4): 2435-44.
21.
Lee, J. T., Jr. and J. A. McCubrey (2002). "The Raf/MEK/ERK signal transduction cascade as a target for chemotherapeutic intervention in leukemia." Leukemia 16(4): 486-507.
22.
Davis, R. J. (2000). "Signal transduction by the JNK group of MAP kinases." Cell 103(2): 239-52.
23.
Sanchez, I., R. T. Hughes, Mayer BJ, Yee K, et.al (1994). "Role of SAPK/ERK kinase-1 in the stress-activated pathway regulating transcription factor c-Jun." Nature 372(6508): 794-8.
24.
Chang, L. and M. Karin (2001). "Mammalian MAP kinase signalling cascades." Nature 410(6824): 37-40.
25.
Cavanaugh, J. E., J. Ham, Hetman M, Poser S, Yan C, Xia Z. (2001). "Differential regulation of mitogenactivated protein kinases ERK1/2 and ERK5 by neurotrophins, neuronal activity, and cAMP in neurons." J Neurosci 21(2): 434-43.
26.
Watson, F. L., H. M. Heerssen, Bhattacharyya A, Klesse L, Lin MZ, Segal RA.. (2001). "Neurotrophins use the Erk5 pathway to mediate a retrograde survival response." Nat Neurosci 4(10): 981-8.
27.
Sun, W., X. Wei, Kesavan K, et al.. (2003). "MEK kinase 2 and the adaptor protein Lad regulate extracellular signal-regulated kinase 5 activation by epidermal growth factor via Src." Mol Cell Biol 23(7): 2298-308.
28.
Kyriakis, J. M. and J. Avruch (2001). "Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation." Physiol Rev 81(2): 807-69.
29.
Stork, P.J. and Schmitt, J.M. (2002) Crosstalk between cAMP and MAP kinase signaling in the regulation of cell proliferation. Trends Cell Biol. 12, 258-266.
30.
Lewis, T.S. et al. (1998) Signal transduction through MAP kinase cascades. Adv. Cancer Res. 74, 49-139.
31.
Giancotti, F.G. and Ruoslahti, E. (1999) Integrin signaling. Science 285, 1028-1032.
32.
Porter, A.C. and Vaillancourt, R.R. (1998) Tyrosine kinase receptor-activated signal transduction pathways which lead to oncogenesis. Oncogene 17, 1343-1352.
33.
Rane, S.G. (1999) Ion channels as physiological effectors for growth factor receptor and Ras/ERK signaling pathways. Adv. Second Messenger Phosphoprotein Res. 33, 107-127.
34.
Verma, A. and L. C. Platanias (2002). "Signaling via the interferon-alpha receptor in chronic myelogenous leukemia cells." Leuk Lymphoma 43(4): 703-9.
35.
Patel, R., Bartosch B, Blank JL. (1998). "p21WAF1 is dynamically associated with JNK in human T-lymphocytes during cell cycle progression." J Cell Sci 111 ( Pt 15): 2247-55.
36.
Gabai, V. L., A. B. Meriin, Mosser DD, Caron AW, Rits S, Shifrin VI, Sherman MY. (1997). "Hsp70 prevents activation of stress kinases. A novel pathway of cellular thermotolerance." J Biol Chem 272(29): 18033-7.
37.
Hirosumi, J., G Tuncman G, Chang L, Gorgun CZ, Uysal KT, Maeda K, Karin M, Hotamisligil GS. (2002). "A central role for JNK in obesity and insulin resistance." Nature 420(6913): 333-6.
38.
Dong, C., Yang DD, Wysk M, Whitmarsh AJ, Davis RJ, Flavell RA. (1998). "Defective T cell differentiation in the absence of Jnk1." Science 282(5396): 2092-5.
39.
Fuchs, S. Y., V. Adler, Buschmann T, Wu X, Ronai Z. (1998a). "Mdm2 association with p53 targets its ubiquitination." Oncogene 17(19): 2543-7.
40.
Fuchs, S. Y., V. Adler, Buschmann T, Yin Z, Wu X, Jones SN, Ronai Z. (1998b). "JNK targets p53 ubiquitination and degradation in nonstressed cells." Genes Dev 12(17): 2658-63.
41.
Fuchs, S. Y., V. Adler, Pincus MR, Ronai Z. (1998c). "MEKK1/JNK signaling stabilizes and activates p53." Proc Natl Acad Sci U S A 95(18): 10541-6.
42.
Zarubin, T. and J. Han (2005). "Activation and signaling of the p38 MAP kinase pathway." Cell Res 15(1): 11-8.
43.
Baldwin, A. S., Jr. (1996). "The NF-kappa B and I kappa B proteins: new discoveries and insights." Annu Rev Immunol 14: 649-83.
44.
Orlowski RZ, Baldwin AS Jr. NF-kappaB as a therapeutic target in cancer. Trends Mol Med. 2002 Aug;8(8):385-9. Review.
45.
Sen, R. and D. Baltimore (1986). "Inducibility of kappa immunoglobulin enhancerbinding protein Nf-kappa B by a posttranslational mechanism." Cell 47(6): 921-8.
46.
Lee, J. I. and G. J. Burckart (1998). "Nuclear factor kappa B: important transcription factor and therapeutic target." J Clin Pharmacol 38(11): 981-93.
47.
Sanchez-Perez, I., J. R. Murguia, Perona R. (1998). "Cisplatin induces a persistent activation of JNK that is related to cell death." Oncogene 16(4): 533-40.
48.
Sanchez-Perez, I., S. A. Benitah, Martinez-Gomariz M, Lacal JC, Perona R. (2002). "Cell stress and MEKK1-mediated c-Jun activation modulate NFkappaB activity and cell viability." Mol Biol Cell 13(8): 2933-45.
49.
Malinin, N. L., M. P. Boldin, Kovalenko AV, Wallach D. (1997). "MAP3K-related kinase involved in NFkappaB induction by TNF, CD95 and IL-1." Nature 385(6616): 540-4.
50.
Maggirwar, S. B., S. Ramirez, Tong N, Gelbard HA, Dewhurst S. (2000). "Functional interplay between nuclear factor-kappaB and c-Jun integrated by coactivator p300 determines the survival of nerve growth factor-dependent PC12 cells." J Neurochem 74(2): 527-39.
51.
Tang, G., Y. Minemoto, Dibling B, Purcell NH, Li Z, Karin M, Lin A. (2001). "Inhibition of JNK activation through NFkappaB target genes." Nature 414(6861): 313-7.
52.
Carter, A. B., Knudtson KL, Monick MM, Hunninghake GW. (1999). "The p38 mitogen-activated protein kinase is required for NF-kappaB-dependent gene expression. The role of TATAbinding protein (TBP)." J Biol Chem 274(43): 30858-63.
53.
Alpert, D., P. Schwenger, Han J, Vilcek J. (1999). "Cell stress and MKK6b-mediated p38 MAP kinase activation inhibit tumor necrosis factor-induced IkappaB phosphorylation and NF-kappaB activation." J Biol Chem 274(32): 22176-83.
54.
Degli-Esposti, M. A., W. C. Dougall, Smolak PJ, Waugh JY, Smith CA, Goodwin RG. (1997). "The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain." Immunity 7(6): 813-20.
55.
Jeremias, I., C. Kupatt C, Baumann B, Herr I, Wirth T, Debatin KM. (1998). "Inhibition of nuclear factor kappaB activation attenuates apoptosis resistance in lymphoid cells." Blood 91(12): 4624- 31.
56.
Beg, A. A. and D. Baltimore (1996). "An essential role for NF-kappaB in preventing TNF-alpha-induced cell death." Science 274(5288): 782-4.
57.
Ponton, A., M. V. Clement, Stamenkovic I. (1996). "The CD95 (APO-1/Fas) receptor activates NF-kappaB independently of its cytotoxic function." J Biol Chem 271(15): 8991-5.
58.
Das, K. C. and C. W. White (1997). "Activation of NF-kappaB by antineoplastic agents. Role of protein kinase C." J Biol Chem 272(23): 14914-20.
59.
Webster, G. A. and N. D. Perkins (1999). "Transcriptional cross talk between NFkappaB and p53." Mol Cell Biol 19(5): 3485-95.
60.
Boland, M. P., K. A. Fitzgerald, O'Neill LA.. (2000). "Topoisomerase II is required for mitoxantrone to signal nuclear factor kappa B activation in HL60 cells." J Biol Chem 275(33): 25231-8.
61.
Boland, M. P., S. J. Foster, O'Neill LA. (1997). "Daunorubicin activates NFkappaB and induces kappaB-dependent gene expression in HL-60 promyelocytic and Jurkat T lymphoma cells." J Biol Chem 272(20): 12952-60.
62.
Boland, M. P. and L. A. O'Neill (1998). "Ceramide activates NFkappaB by inducing the processing of p105." J Biol Chem 273(25): 15494-500.
63.
Boland, M. P. (2001). "ADN damage signalling and NF-kappaB: implications for survival and death in mammalian cells." Biochem Soc Trans 29(Pt 6): 674-8.
64.
Sanz, C., C. Richard, Prosper F, Fernandez-Luna JL. (2002). "Nuclear factor k B is activated in myelodysplastic bone marrow cells." Haematologica 87(9): 1005-6.
65.
Slater, A. F., Kimland M, Jiang SA, Orrenius S. (1995). "Constitutive nuclear NF kappa B/rel ADN-binding activity of rat thymocytes is increased by stimuli that promote apoptosis, but not inhibited by pyrrolidine dithiocarbamate." Biochem J 312 ( Pt 3): 833-8.
66.
Kronke, M. and Adam-Klages, S. (2002) Role of caspases in TNF-mediated regulation of cPLA(2). FEBS Lett. 531, 18-22.
67.
Shi, Y. (2002) Mechanisms of caspase activation and inhibition during apoptosis. Mol Cell. 9, 459-470.
68.
Beere, H.M. (2004) "The stress of dying": the role of heat shock proteins in the regulation of apoptosis. J. Cell Sci. 117, 2641-2651.
69.
Siskind, L. J. and M. Colombini (2000). "The lipids C2-and C16-ceramide form large stable channels. Implications for apoptosis." J Biol Chem 275(49): 38640-4.
70.
Kulik, G. and M. J. Weber (1998). "Akt-dependent and -independent survival signaling pathways utilized by insulin-like growth factor I." Mol Cell Biol 18(11): 6711-8
71.
Song, G., Ouyang G, Bao S. (2005). "The activation of Akt/PKB signaling pathway and cell survival." J Cell Mol Med 9(1): 59-71.
72.
Chang, F., Steelman LS, Shelton JG, Lee JT, Navolanic PM, Blalock WL, Franklin R, McCubrey JA. (2003). "Regulation of cell cycle progression and apoptosis by the Ras/Raf/MEK/ERK pathway (Review)." Int J Oncol 22(3): 469- 80.
73.
Koumenis, C., R. Alarcon, Hammond E, Sutphin P, Hoffman W, Murphy M, Derr J, Taya Y, Lowe SW, Kastan M, Giaccia A. (2001). "Regulation of p53 by hypoxia: dissociation of transcriptional repression and apoptosis from p53-dependent transactivation." Mol Cell Biol 21(4): 1297-310.
74.
Linke, S. P., K. C. Clarkin, Di Leonardo A, Tsou A, Wahl GM (1996). "A reversible, p53 dependent G0/G1 cell cycle arrest induced by ribonucleotide depletion in the absence of detectable ADN damage." Genes Dev 10(8): 934-47.
75.
Sablina, A. A., P. M. Chumakov, Levine AJ, Kopnin BP (2001). "p53 activation in response to microtubule disruption is mediated by integrin-Erk signaling." Oncogene 20(8): 899-909.
76.
Webley, K., J. A. Bond, Jones CJ, Blaydes JP, Craig A, Hupp T, Wynford-Thomas D (2000). "Posttranslational modifications of p53 in replicative senescence overlapping but distinct from those induced by ADN damage." Mol Cell Biol 20(8): 2803-8.
77.
Jin, S. and A. J. Levine (2001). "The p53 functional circuit." J Cell Sci 114(Pt 23): 4139-40.
78.
Balint, E. E. and K. H. Vousden (2001). "Activation and activities of the p53 tumour suppressor protein." Br J Cancer 85(12): 1813-23.
79.
Yonish-Rouach, E., Resnitzky D, Lotem J, Sachs L, Kimchi A, Oren M. (1991). "Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6." Nature 352(6333): 345-7.
80.
Bouvard, V., Zaitchouk T, Vacher M, Duthu A, Canivet M, Choisy-Rossi C, Nieruchalski M, May E. (2000). "Tissue and cell-specific expression of the p53-target genes: bax, fas, mdm2 and waf1/p21, before and following ionising irradiation in mice." Oncogene 19(5): 649-60.
81.
O'Connor, L., Harris AW, Strasser A. (2000). "CD95 (Fas/APO-1) and p53 signal apoptosis independently in diverse cell types." Cancer Res 60(5): 1217-20.
82.
Wu, G. S., Burns TF, McDonald ER 3rd, Jiang W,et al. (1997). "KILLER/DR5 is a ADN damage-inducible p53-regulated death receptor gene." Nat Genet 17(2): 141-3.
83.
Attardi, L. D., E. E. Reczek, Cosmas C, Demicco EG, McCurrach ME, Lowe SW, Jacks T. (2000). "PERP, an apoptosis-associated target of p53, is a novel member of the PMP-22/gas3 family." Genes Dev 14(6): 704-18.
84.
Chen, Z., T. B. Gibson, F. Robinson, L. Silvestro, G. Pearson, B. Xu, A. Wright, C. Vanderbilt, and M. H. Cobb.(2001). "MAP kinases". Chem. Rev. 101:2449-2476.
85.
Lewis, T. S., P. S. Shapiro, and N. G. Ahn. (1998). "Signal transduction through MAP kinase cascades." Adv. Cancer Res. 74:49-139.
86.
Xia, Y., C. Makris, B. Su, E. Li, J. Yang, G. R. Nemerow, and M. Karin. (2000) "MEK kinase 1 is critically required for c-Jun N-terminal kinase activation by proinflammatory stimuli and growth factor-induced cell migration." Proc. Natl. Acad. Sci. USA 97:5243-5248
87.
Yujiri, T., S. Sather, G. R. Fanger, and G. L. Johnson. (1998) "Role of MEKK1 in cell survival and activation of JNK and ERK pathways defined by targeted gene disruption." Science 282:1911-1914.
88.
Campbell, S. L., R. Khosravi-Far, K. L. Rossman, G. J. Clark, and C. J.Der. (1998) "Increasing complexity of Ras signaling." Oncogene 17:1395-1413.
89.
Wood, K., C. Sarnecki, T. M. Roberts, and J. Blenis. (1992) "c-Ras mediates nerve growth factor receptor modulation of three signal-transducing protein kinases: MAP kinase, Raf-1 and RSK." Cell 68:1041-1050.
90.
Geyer, M., and A. Wittinghofer. (1997) "GEFs, GAPs, GDIs and effectors: taking a closer (3D) look at the regulation of Ras-related GTP-binding proteins." Curr. Opin. Struct. Biol. 7:786-792.
91.
Chong, H., H. G. Vikis, and K. L. Guan. (2003) "Mechanisms of regulating the Raf kinase family." Cell Signal. 15:463-469.
92.
Downward, J. (2003) "Targeting RAS signalling pathways in cancer therapy." Nat. Rev. Cancer 3:11-22
93.
Mercer, K. E., and C. A. Pritchard. (2003) "Raf proteins and cancer: B-Raf is identified as a mutational target. Biochim. Biophys." Acta 1653:25-40.
94.
Pouyssegur, J., V. Volmat, and P. Lenormand. (2002) "Fidelity and spatiotemporal control in MAP kinase (ERKs) signalling." Biochem. Pharmacol 64:755-763.
95.
Kohno, M., and J. Pouyssegur. (2003) "Pharmacological inhibitors of the ERK signaling pathway: application as anticancer drugs."Prog. Cell Cycle Res. 5:219-224.
96.
Ballif, B. A., and J. Blenis. (2001.) "Molecular mechanisms mediating mammalian mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK cell survival signals." Cell Growth Differ. 12:397-408.
97.
Frodin, M., and S. Gammeltoft. (1999). "Role and regulation of 90 kDa ribosomal S6 kinase (RSK) in signal transduction. Mol." Cell. Endocrinol. 151:65-77.
98.
Liat Abovich Gilad, Tali Bresler, Julia Gnainsky, Patricia Smirnoff and Betty Schwartz Regulation of vitamin D receptor expression via estrogen-induced activation of the ERK 1/2 signaling pathway in colon and breast cancer cells Journal of Endocrinology (2005) 185, 577-592
99.
Thompson, L P Bron and P Hersey L Zhuang, C S Lee, R A Scolyer, S W McCarthy, A A Palmer, X D Zhang,(2005) "Kinase (ERK) pathway in human melanoma activation of the extracellular signal regulated" J. Clin. Pathol. 58;1163-1169
100.
Kostyantyn Krysan, KL. Reckamp, Harnisha Dalwadi, et al "Prostaglandin E2 Activates Mitogen-Activated Protein Kinase/Erk Pathway Signaling and Cell Proliferation in Non-Small Cell Lung Cancer Cells in an Epidermal Growth Factor Receptor-Independent Manner" Cancer Res 2005; 65: (14). July 15, 2005 102
101.
Gerhard Christofori1. New signals from the invasive front. NATURE|Vol 441|25 May 2006. Bergers, G. & Benjamin, L. E. "Tumorigenesis and the angiogenic switch." Nature Rev. Cancer 3, 401-410 (2003).
102.
Folkman, J. "Role of angiogenesis in tumor growth and metastasis." Semin. Oncol. 29, 15-18 (2002).
103.
Achen, M. G., McColl, B. K. & Stacker, S. A. "Focus on lymphangiogenesis in tumor metastasis." Cancer Cell 7, 121-127 (2005).
104.
Saharinen, P., Tammela, T., Karkkainen, M. J. & Alitalo, K. "Lymphatic vasculature: development, molecular regulation and role in tumor metastasis and inflammation." Trends Immunol. 25, 387-395 (2004).
105.
Houle F, Huot J. "Dysregulation of the endothelial cellular response to oxidative stress in cancer." Mol Carcinog. 2006 Jun;45(6):362-7. Review.104
106.
Wan PT, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM, Jones CM, Marshall CJ, Springer CJ, Barford D, Marais R; Cancer Genome Project. "Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF." Cell. 2004 Mar 19;116(6):855-67.
107.
Do NY, Lim SC, Im TS. "Expression of c-erbB receptors, MMPs and VEGF in squamous cell carcinoma of the head and neck."Oncol Rep. 2004 Aug;12(2):229-37.
108.
Ciardiello F, Caputo R, Bianco R, et al "Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor." Clin Cancer Res. 2000 May;6(5):2053-63.
109.
Holbro T, Beerli RR, Maurer F, Koziczak M, Barbas CF 3rd, Hynes NE. "The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation." Proc Natl Acad Sci U S A. 2003 Jul 22;100(15):8933-8. Epub 2003 Jul 9.
110.
Bieche I, Onody P, Tozlu S, Driouch K, Vidaud M, Lidereau R. "Prognostic value of ERBB family mRNA expression in breast carcinomas."Int J Cancer. 2003 Sep 20;106(5):758-65.
111.
Sithanandam G, Smith GT, Masuda A, Takahashi T, Anderson LM, Fornwald LW. "Cell cycle activation in lung adeno carcino ma cells by the ErbB3/phosphatidylinositol 3-kinase/Akt pathway." Carcinogenesis. 2003 Oct;24(10):1581-92. Epub 2003 Aug 1.
112.
Junttila TT, Laato M, Vahlberg T, Soderstrom KO, Visakorpi , Isola J, Elenius K. "Identification of patients with transitional cell carcinoma of the bladder overexpressing ErbB2, ErbB3, or specific ErbB4 isoforms: real-time reverse transcription-PCR analysis in estimation of ErbB receptor status from cancer patients." Clin Cancer Res. 2003 Nov 1;9(14):5346-57.
113.
Schaefer KL, Brachwitz K, Wai DH, Braun Y, Diallo R, Korsching E, Eisenacher M, Voss R, Van Valen F, Baer C, Selle B, Spahn L, Liao SK, Lee KA, Hogendoorn PC, Reifenberger G, Gabbert HE, Poremba C. "Expression profiling of t(12;22) positive clear cell sarcoma of soft tissue cell lines reveals characteristic up-regulation of potential new marker genes including ERBB3."Cancer Res. 2004 May 15;64(10):3395-405.
114.
Shintani S, Funayama T, Yoshihama Y, Alcalde RE, Matsumura T. "Prognostic significance of ERBB3 overexpression in oral squamous cell carcinoma." Cancer Lett. 1995 Aug 16;95(1-2):79-83.
115.
Vakar-Lopez F, Cheng CJ, Kim J, Shi GG, Troncoso P, Tu SM, Yu-Lee LY, Lin SH. "Up-regulation of MDA-BF-1, a secreted isoform of ErbB3, in metastatic prostate cancer cells and activated osteoblasts in bone marrow." J Pathol. 2004 Jun;203(2):688-95.
116.
Bei R, Budillon A, Masuelli L, Cereda V, et al "Frequent overexpression of multiple ErbB receptors by head and neck squamous cell carcinoma contrasts with rare antibody immunity in patients." J Pathol. 2004 Nov;204(3):317-25.
117.
Thomasson M, Hedman H, Junttila TT, Elenius K, Ljungberg B, Henriksson R. "ErbB4 is downregulated in renal cell carcinoma--a quantitative RT-PCR and immunohistochemical analysis of the epidermal growth factor receptor family." Acta Oncol. 2004;43(5):453-9.
118.
Kato S, Kobayashi T, Yamada K, Nishii K, Sawada H, Ishiguro H, Itoh M, Funahashi H, Nagasaka A. "Expression of erbB receptors mRNA in thyroid tissues." Biochim Biophys Acta. 2004 Aug 4;1673(3):194-200.
119.
Andersson U, Guo D, Malmer B, Bergenheim AT, Brannstrom T, Hedman H, Henriksson R. "Epidermal growth factor receptor family (EGFR, ErbB2-4) in gliomas and meningiomas."Acta Neuropathol (Berl). 2004 Aug;108(2):135-42. Epub 2004 May 18.
120.
Tovey SM, Witton CJ, Bartlett JM, Stanton PD, Reeves JR, Cooke TG. "Outcome and human epidermal growth factor receptor (HER) 1-4 status in invasive breast carcinomas with proliferation indices evaluated by bromodeoxyuridine labelling. "Breast Cancer Res. 2004;6(3):R246-51. Epub 2004 Mar 23.
121.
Wright JH, Wang X, Manning G, LaMere BJ, Le P, Zhu S, Khatry D, Flanagan PM, Buckley SD, Whyte DB, Howlett AR, Bischoff JR, Lipson KE, Jallal B. "The STE20 kinase HGK is broadly expressed in human tumor cells and can modulate cellular transformation, invasion, and adhesion."Mol Cell Biol. 2003 Mar;23(6):2068-82.
122.
Platanias LC. "The p38 mitogen-activated protein kinase pathway and its role in interferon signaling." Pharmacol Ther. 2003 May;98(2):129-42. Review.
123.
Andreakos E. "Targeting cytokines in autoimmunity: new approaches, new promise."Expert Opin Biol Ther. 2003 Jun;3(3):435-47. Review.
124.
Schultz RM. "Potential of p38 MAP kinase inhibitors in the treatment of cancer."Prog Drug Res. 2003;60:59-92. Review.
125.
Alavi A, Hood JD, Frausto R, Stupack DG, Cheresh DA. "Role of Raf in vascular protection from distinct apoptotic stimuli." Science. 2003 Jul 4;301(5629):94-6.
126.
Simon R, Richter J, Wagner U, Fijan A, Bruderer J, Schmid U, Ackermann D, Maurer R, Alund G, Knonagel H, Rist M, Wilber K, Anabitarte M, Hering F, Hardmeier T, Schonenberger A, Flury R, Jager P, Fehr JL, Schraml P, Moch H, Mihatsch MJ, Gasser T, Sauter G. "High-throughput tissue microarray analysis of 3p25 (RAF1) and 8p12 (FGFR1) copy number alterations in urinary bladder cancer." Cancer Res. 2001 Jun 1;61(11):4514-9.
127.
Mao X, Orchard G, Lillington DM, Russell-Jones R, Young BD, Whittaker S. "Genetic alterations in primary cutaneous CD30+ anaplastic large cell lymphoma." Genes Chromosomes Cancer. 2003 Jun;37(2):176-85.
128.
Tupputi M, di Martino MR, Mostarda A, Piras V. Anesthesia and pregnancy in oral medicine" Minerva Anestesiol. 1992 Oct;58(10):1051-6. Review. Italian.
129.
Hui AB, Lo KW, Teo PM, To KF, Huang DP. "Genome wide detection of oncogene amplifications in nasopharyngeal carcinoma by array based comparative genomic hybridization." Int J Oncol. 2002 Mar;20(3):467-73. Erratum in: Int J Oncol. 2002 Aug;21(2):451.
130.
Arteaga CL: "The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia." J Clin Oncol 19:32S-40S., 2001
131.
Cortes-Funes H, Gomez C, Rosell R, et al. "Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients." Ann Oncol. 2005 Jul;16(7):1081-6. Epub 2005 Apr 25
132.
Gomez et al. "A Phase II, Randomized Trial Using the Small Molecule . Kinase Inhibitor Lapatinib as a first-Line Treatment in Patients with FISH Positive Advanced or Metastatic Breast Cancer." Proc ASCO2005 #3046
133.
Hidalgo M, Siu L, Nemunaitis J, Rizzo J, et al: "Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies." J Clin Oncol 19:3267-3279, 2001
134.
Baselga J, Albanell J, Ruiz A, et al: Phase II and tumor pharmacodynamic study of gefinitib (ZD1839) in patients with advanced breast cancer. J Clin Oncol 2005
135.
Jimeno A. Hidalgo M. Promises and pitfalls in the prediction of antiepidermal growth factor receptor activity. Expert Rev Anticancer Ther. 2005 Aug;5(4):727-35.
136.
Mendelsohn J:Targeting the epidermal growth factor receptor for cancer therapy. J Clin Oncol 20:1s-13, 2002
137.
Miller et al. Phase II study of SU11248, a multitargeted receptor tyrosine kinase inhibitor (TKI), in patients (pts) with previously treated metastatic breast cancer (MBC). Proc ASCO 2005, #563136- 140
138.
Mendelsohn J, et al. J Clin Oncol 2002;20:1S-13S. Baselga J, et al. J Clin Oncol 2000;18:904-914.
139.
Saltz LB, et al. J Clin Oncol 2004;22:1201-1208.
140.
Saltz LB, et al. Proc Am Soc Clin Oncol 2001;20:3a(A7)
141.
Cunningham D, et al. N Engl J Med 2004;351:337-45.
142.
Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (the IDEAL 1 Trial). J Clin Oncol 2003;21:2237-46. [Erratum, J Clin Oncol 2004;22:4811.]
143.
Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003;290:2149-58.
144.
Perez-Soler R, Chachoua A, Hammond LA, et al. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 2004;22:3238-47.
145.
Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39.
146.
Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-500.
147.
Shah NP,Tran C, Lee FY, Chen P, Norris D, Sawyers CL. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004;305:399-401.
148.
Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutation and resistance of non-small cell lung cancer to gefitinib. N Engl J Med 2005;352:786-92.
149.
Blencke S, Ullrich A, Daub H. Mutation of threonine 766 in the epidermal growth factor receptor reveals a hotspot for resistance formation against selective tyrosine kinase inhibitors. J Biol Chem 2003;278:15435-40.
150.
Thacher N, et a. Lancet 2005 (en prensa).
151.
Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005 Jul 14;353(2):200-2.
152.
Hurwitz H, et al. N Engl J Med 2004;350:2335-42
153.
Kabbinavar FF, et al. J Clin Oncol 2005;23:3697-705
154.
Kabbinavar FF, et al. J Clin Oncol 2005;23:3706-12
155.
Giantonio B, et al. Proc Am Soc Clin Oncol 2005;23:A1.
156.
Markku Miettinen, MD WA'El El-rifai, MD Leslie H et al."Evaluation and prognosis of gastrointestinal stromal tumors: A review." Human pathology Vol33,nº5:478-483.
157.
Druker BJ, Tamura S, Buchdunger E et al. "Effects of a selective inhibitor af the Abl tyrosine Kinase on the growth of Bcr-Abl positive cells." Nat. Med 1996; 2: 561-566
158.
Druker BJ, Talpaz M, Resta DJ et al. "Efficacy and safety of an specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukaemia" .N England J Med 344:1031-1037,2001.
159.
Hirota S,Isozaki K,Moriyama Y et al. "Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors." Science. 279:577-580,1998.
160.
Joensuu H, Roberts PJ, Sarlomo-Rikala M, Andersson LC, Tervahartiala P, Tuveson D et al. "Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor." N Engl J Med 2001; 344: 1052
161.
Demetri GD, von Mehren M, Blanke CD, et al. "Efficacy and safety of Imatinib mesylate in advanced gastrointestinal stromal tumors." N. Engl. J. Med 2220; 22:472-480.
162.
Van Oosterom AT, Judson I, Verweij J, Stroobants S, Donato di Paola E, Dimitrijevic S et al."Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study." Lancet 2001; 358: 1421-1423.
163.
MH Ryu. "Efficacy of imatinib mesylate in metastatic or unresectable malignant gastrointestinal stromal tumor (GIST)."ASCO 2003.Abstract No: 3312.
164.
C. Rankin, M von Mehren, C Blanke, et al. "Dose effect of imatinib in patients with metastatic GISTPhase III Sarcoma Group Srtudy S0033." ASCO 2004.Abstract No: 9005.
165.
MC Heinrich, CL Corless, GD Demetri et al. "Kinase mutations and Imatinib response in patients with metastatic Gastrointestinal Stromal Tunmor." J. Clin. Oncol. 2003; vol 21, nº 23: 4342-4349
166.
Verweij J, Casali PG, Zalcberg J et al. "Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial." Lancet. 2004 Sep 25-Oct 1;364(9440):1127-34.
167.
Martin J, Poveda A, Llombart-Bosch A, Ramos R et al. "Spanish Group for Sarcoma Research. Deletions affecting codons 557-558 of the c-KIT gene indicate a poor prognosis in patients with completely resected gastrointestinal stromal tumors: a study by the Spanish Group for Sarcoma Research (GEIS)." J Clin Oncol. 2005 Sep 1;23(25):6190-8.
168.
Van Glabbeke M,Verweij J, Casali PG, Le Cesne et al. "Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group study." J Clin Oncol. 2005 Aug 20;23(24):5795-804.
169.
Demetri GD, Van Oosterom A, Blakstein M, et al. "Phase III, multicenter, randomized, Double-blind, Placebo-controled trial of SU11248 in Patients following failure to Imatinib for Metastatic GIST." ASCO 2005, Abstract 4000
170.
Miller KD, Burnstein HJ, Elias AD, et al. Phase II study of SU11248, a multi-targeted tyrosine kinase inhibitor in patients with previously treated metastatic breast cancer. ASCO 2005, Abstract 563
171.
Motzer R, Rini B, Michaelson M, et al. Phase II trials show antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma. ASCO 2005, Abstract 4508.